WO2019007317A1 - 一种药物组合物及其制备方法 - Google Patents
一种药物组合物及其制备方法 Download PDFInfo
- Publication number
- WO2019007317A1 WO2019007317A1 PCT/CN2018/094211 CN2018094211W WO2019007317A1 WO 2019007317 A1 WO2019007317 A1 WO 2019007317A1 CN 2018094211 W CN2018094211 W CN 2018094211W WO 2019007317 A1 WO2019007317 A1 WO 2019007317A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solid dispersion
- solid
- active ingredient
- carrier material
- pharmaceutically acceptable
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- B cell lymphoma is one of the common malignant tumors affecting human health, accounting for 70-80% of malignant lymphoma, and the incidence rate is increasing year by year. It is one of the common malignant tumors in China. The occurrence of B cell lymphoma is affected by a variety of factors including genetic factors, biological factors, and physical and chemical factors. B-cell lymphoma has a poor prognosis and survival is still low under current treatment regimens.
- BTK inhibition of BTK activity inhibits the activity of transcription factors such as NF- ⁇ B, thereby inhibiting the release of inflammatory factors and reducing the symptoms of inflammation.
- the BTK small molecule inhibitor HM61713 developed by Hanmei Company has a good anti-arthritis effect before clinical practice, and is currently undergoing Phase I clinical trial.
- the solid dispersion of the present disclosure has a weight ratio of the carrier material to the active ingredient or a pharmaceutically acceptable salt thereof, and may be at most 0.5:1.
- the higher the content of the carrier material in the present disclosure the easier it is to change the active ingredient from crystalline to amorphous, and the higher the bioavailability of the corresponding solid dispersion.
- the weight ratio of carrier material to active ingredient or pharmaceutically acceptable salt thereof in the present disclosure may range from 0.5:1 to 4:1, and in embodiments may be 0.5:1.
- the method for removing an organic solvent is known or can be determined by a person skilled in the art, and a method in which a macropolar organic solution is added dropwise to a low polar solvent or a water solvent to precipitate a solid, that is, a method for dialysis Or a dialysis method; it can also be spray dried or dried under reduced pressure.
- the solid dispersion described in the present disclosure is subjected to dissolution measurement by the second method (paddle method) of the four-part general dissolution test of the Chinese Pharmacopoeia 2015 edition. 1000 ml of a 0.15% aqueous solution of SDS was used as the dissolution medium, and the dissolution test was carried out at 37 ⁇ 0.5 ° C at a paddle speed of 75 rpm.
- the pharmaceutical excipients or reagents of the present disclosure may be derived from commercial sources such as hypromellose acetate succinate; Compound A: (R)-4-amino-1-(1-(but-2-alkynyl)pyrrole Alkan-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazine-7-
- the ketone or a pharmaceutically acceptable salt thereof can be obtained by the method described in Example 109 of WO2016007185.
- Figure 1 X-ray diffraction pattern of the drug substance Compound A.
- Compound A and hypromellose acetate succinate were prepared by coprecipitation to prepare a solid dispersion, and the solid dispersion was pulverized, and a prescribed amount of solid dispersion, lactose and crystallite were weighed according to the designed prescription.
- Cellulose, croscarmellose sodium, granulated with polyvinylpyrrolidone as a binder poured into a granulation tank, mixed uniformly, then added with a binder to granulate; wet the wet material Granules and drying treatment, then dry granules (dryness less than 3%), add external ingredients, and mix well.
- the resulting total mixed granules were compressed into tablets.
- the specific prescriptions are carried out in the proportions in Table 8.
- Example 14 tablets were placed at 25 ° C / 60% RH and 40 ° C / 75% RH during the investigation period.
- the data are as follows:
- 0.6 mL of blood was taken from the extremities before and after administration and at 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12, 24, 72 h after administration, and placed in an ethylenediaminetetraacetic acid (EDTA) anticoagulation tube, 3500 rpm. After centrifugation for 10 min (4 ° C), the plasma was separated and stored at -70 ° C for testing.
- EDTA ethylenediaminetetraacetic acid
- the concentration of the prodrug in the plasma and the dosing solution was determined by liquid chromatography-tandem mass spectrometry (LC/MS/MS).
- the obtained plasma concentrations were calculated using the non-compartmental model of Phoenix WinNonlin 6.4 software to determine the pharmacokinetic parameters after Beagle administration. The results are shown in Table 11.
Abstract
Description
Claims (10)
- 一种固体分散体,含有活性成分(R)-4-氨基-1-(1-(丁-2-炔酰基)吡咯烷-3-基)-3-(4-(2,6-二氟苯氧基)苯基)-1,6-二氢-7H-吡咯并[2,3-d]哒嗪-7-酮或其可药用盐,和载体材料,所述载体材料选自醋酸羟丙甲纤维素琥珀酸酯、羟丙甲纤维素邻苯二甲酸酯,优选为醋酸羟丙甲纤维素琥珀酸酯。
- 根据权利要求1所述的固体分散体,其特征在于所述载体材料和活性成分的重量比不小于0.5:1。
- 根据权利要求1或2所述的固体分散体,其特征在于所述载体材料和活性成分的重量比为0.5:1~4:1,优选为0.8:1~3:1,更优选为1:1~2:1。
- 根据权利要求1~3任一项所述的固体分散体,其特征在于所述固体分散体由活性成分(R)-4-氨基-1-(1-(丁-2-炔酰基)吡咯烷-3-基)-3-(4-(2,6-二氟苯氧基)苯基)-1,6-二氢-7H-吡咯并[2,3-d]哒嗪-7-酮或其可药用盐,和载体材料组成。
- 一种制备权利要求1~4任一项所述的固体分散体的方法,其包括将载体材料与活性成分或其可药用盐共同溶解于有机溶剂中,或将载体材料混悬分散在活性成分或其可药用盐的有机溶剂中,而后除去有机溶剂后制得固体分散体。
- 根据权利要求5所述的方法,其特征在于采用冲析法去除有机溶剂。
- 一种固体制剂,其包含权利要求1~4任一项所述的固体分散体,所述固体制剂选自片剂、丸剂、颗粒剂或胶囊剂。
- 根据权利要求7所述的固体制剂,其特征在于所述固体制剂还包含药学上可接受的赋形剂,所述赋形剂选自崩解剂、填充剂、粘合剂、润滑剂中的至少一种。
- 根据权利要求8所述的固体制剂,其特征在于所述固体制剂中含有:1)10mg~500mg重量的活性成分或其可药用盐;2)5~15%重量的崩解剂;3)30~90%重量的填充剂;4)0.5~10%重量的粘合剂;5)0.1~5%重量的润滑剂。
- 根据权利要求7~9任一项所述的固体制剂,其特征在于,在0.15%的十二烷基硫酸钠(SDS)水溶液介质条件下,所述固体制剂中活性成分的溶出度(%),45min保持在85%或更高,优选为90%或更高。
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2019015612A MX2019015612A (es) | 2017-07-04 | 2018-07-03 | Composicion farmaceutica y metodo para preparar el mismo. |
JP2019568286A JP7190452B2 (ja) | 2017-07-04 | 2018-07-03 | 医薬組成物及びその製造方法 |
AU2018296476A AU2018296476B2 (en) | 2017-07-04 | 2018-07-03 | Pharmaceutical composition and method for preparing same |
CA3066046A CA3066046A1 (en) | 2017-07-04 | 2018-07-03 | Pharmaceutical composition and method for preparing same |
CN201880004396.3A CN109963565B (zh) | 2017-07-04 | 2018-07-03 | 一种药物组合物及其制备方法 |
US16/626,910 US11304945B2 (en) | 2017-07-04 | 2018-07-03 | Pharmaceutical composition and method for preparing same |
UAA202000414A UA127413C2 (uk) | 2017-07-04 | 2018-07-03 | Фармацевтична композиція та спосіб її отримання |
EP18828577.9A EP3650025A4 (en) | 2017-07-04 | 2018-07-03 | PHARMACEUTICAL COMPOSITION AND METHOD FOR MANUFACTURING THEREOF |
KR1020207001561A KR20200024237A (ko) | 2017-07-04 | 2018-07-03 | 약학 조성물 및 이를 제조하기 위한 방법 |
RU2020102280A RU2767872C2 (ru) | 2017-07-04 | 2018-07-03 | Фармацевтическая композиция и способ ее получения |
BR112019027473-1A BR112019027473A2 (pt) | 2017-07-04 | 2018-07-03 | composição farmacêutica e método para preparar a mesma |
ZA2019/08090A ZA201908090B (en) | 2017-07-04 | 2019-12-05 | Pharmaceutical composition and method for preparing same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710536705 | 2017-07-04 | ||
CN201710536705.9 | 2017-07-04 | ||
CN201711105075.6 | 2017-11-10 | ||
CN201711105075 | 2017-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019007317A1 true WO2019007317A1 (zh) | 2019-01-10 |
Family
ID=64950432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/094211 WO2019007317A1 (zh) | 2017-07-04 | 2018-07-03 | 一种药物组合物及其制备方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US11304945B2 (zh) |
EP (1) | EP3650025A4 (zh) |
JP (1) | JP7190452B2 (zh) |
KR (1) | KR20200024237A (zh) |
CN (1) | CN109963565B (zh) |
AU (1) | AU2018296476B2 (zh) |
BR (1) | BR112019027473A2 (zh) |
CA (1) | CA3066046A1 (zh) |
MX (1) | MX2019015612A (zh) |
RU (1) | RU2767872C2 (zh) |
UA (1) | UA127413C2 (zh) |
WO (1) | WO2019007317A1 (zh) |
ZA (1) | ZA201908090B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111499642A (zh) * | 2019-01-31 | 2020-08-07 | 江苏恒瑞医药股份有限公司 | 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法 |
WO2020239065A1 (zh) | 2019-05-31 | 2020-12-03 | 江苏恒瑞医药股份有限公司 | 一种固体分散体及其制备方法 |
RU2816913C2 (ru) * | 2019-05-31 | 2024-04-08 | Цзянсу Хэнжуй Медсин Ко., Лтд. | Твердая дисперсия и способ ее получения |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013184572A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
WO2016007185A1 (en) | 2014-07-07 | 2016-01-14 | Eternity Bioscience Inc. | Aminopyridazinone compounds as protein kinase inhibitors |
CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
CN106573002A (zh) * | 2014-08-07 | 2017-04-19 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶抑制剂的新型制剂 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1926476E (pt) * | 2005-08-29 | 2013-07-10 | Sanofi Aventis Us Llc | Dispersões sólidas amorfas de 7-cloro-n,n,5-trimetil-4-oxo-3- fenil-3,5-di-hidro-4h-piridazino[4,5-b]indole-1-acetamida |
EP2155166A2 (en) * | 2007-05-11 | 2010-02-24 | F. Hoffmann-Roche AG | Pharmaceutical compositions for poorly soluble drugs |
JP2013103899A (ja) * | 2011-11-11 | 2013-05-30 | Fuji Chem Ind Co Ltd | 難溶性薬物の新規な固体分散体 |
NZ708272A (en) * | 2013-01-22 | 2020-07-31 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
CA2976811C (en) | 2015-03-10 | 2023-06-27 | Shionogi Inc. | Solid dispersions of ospemifene |
-
2018
- 2018-07-03 EP EP18828577.9A patent/EP3650025A4/en active Pending
- 2018-07-03 WO PCT/CN2018/094211 patent/WO2019007317A1/zh unknown
- 2018-07-03 AU AU2018296476A patent/AU2018296476B2/en active Active
- 2018-07-03 BR BR112019027473-1A patent/BR112019027473A2/pt unknown
- 2018-07-03 UA UAA202000414A patent/UA127413C2/uk unknown
- 2018-07-03 US US16/626,910 patent/US11304945B2/en active Active
- 2018-07-03 CA CA3066046A patent/CA3066046A1/en active Pending
- 2018-07-03 MX MX2019015612A patent/MX2019015612A/es unknown
- 2018-07-03 CN CN201880004396.3A patent/CN109963565B/zh active Active
- 2018-07-03 JP JP2019568286A patent/JP7190452B2/ja active Active
- 2018-07-03 RU RU2020102280A patent/RU2767872C2/ru active
- 2018-07-03 KR KR1020207001561A patent/KR20200024237A/ko not_active Application Discontinuation
-
2019
- 2019-12-05 ZA ZA2019/08090A patent/ZA201908090B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013184572A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
WO2016007185A1 (en) | 2014-07-07 | 2016-01-14 | Eternity Bioscience Inc. | Aminopyridazinone compounds as protein kinase inhibitors |
CN106573001A (zh) * | 2014-07-07 | 2017-04-19 | 永恒生物科技公司 | 作为蛋白激酶抑制剂的氨基哒嗪酮化合物 |
CN106573002A (zh) * | 2014-08-07 | 2017-04-19 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶抑制剂的新型制剂 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111499642A (zh) * | 2019-01-31 | 2020-08-07 | 江苏恒瑞医药股份有限公司 | 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法 |
WO2020239065A1 (zh) | 2019-05-31 | 2020-12-03 | 江苏恒瑞医药股份有限公司 | 一种固体分散体及其制备方法 |
CN113825511A (zh) * | 2019-05-31 | 2021-12-21 | 江苏恒瑞医药股份有限公司 | 一种固体分散体及其制备方法 |
RU2816913C2 (ru) * | 2019-05-31 | 2024-04-08 | Цзянсу Хэнжуй Медсин Ко., Лтд. | Твердая дисперсия и способ ее получения |
Also Published As
Publication number | Publication date |
---|---|
TW201906609A (zh) | 2019-02-16 |
JP2020525415A (ja) | 2020-08-27 |
AU2018296476A1 (en) | 2020-01-16 |
BR112019027473A2 (pt) | 2020-07-07 |
RU2767872C2 (ru) | 2022-03-22 |
RU2020102280A3 (zh) | 2021-09-17 |
EP3650025A1 (en) | 2020-05-13 |
EP3650025A4 (en) | 2021-04-28 |
CN109963565A (zh) | 2019-07-02 |
US11304945B2 (en) | 2022-04-19 |
ZA201908090B (en) | 2021-08-25 |
JP7190452B2 (ja) | 2022-12-15 |
MX2019015612A (es) | 2020-02-26 |
US20200171031A1 (en) | 2020-06-04 |
CA3066046A1 (en) | 2019-01-10 |
KR20200024237A (ko) | 2020-03-06 |
AU2018296476B2 (en) | 2023-11-02 |
CN109963565B (zh) | 2021-09-03 |
RU2020102280A (ru) | 2021-08-04 |
UA127413C2 (uk) | 2023-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014210103B2 (en) | Pharmaceutical composition with improved bioavailability | |
TWI564008B (zh) | 難溶性藥物之溶解性改善製劑 | |
JP6577143B2 (ja) | ブルトンチロシンキナーゼの阻害剤を含む剤形組成物 | |
PT1485094E (pt) | Forma de administração por via oral para 3-[(2-{[4- (hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil- 1h-benzimidazole-5-carbonil)-piridin-2-il-amino]-propionato de etilo ou os seus sais | |
WO2020249001A1 (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
US20170105937A1 (en) | Olaparib co-precipitate and preparation method thereof | |
US9447065B2 (en) | Pharmaceutical composition | |
JP2020521732A (ja) | N−{4−[(6,7−ジメトキシキノリン−4−イル)オキシ]フェニル}−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 | |
WO2019007317A1 (zh) | 一种药物组合物及其制备方法 | |
WO2015132708A1 (en) | Pharmaceutical composition of roflumilast | |
TWI837095B (zh) | 一種醫藥組成物及其製備方法 | |
KR20220113967A (ko) | 비정질 형태의 방향족 헤테로사이클릭 화합물을 함유하는 조성물, 및 이의 제조 방법 및 이의 용도 | |
JPH11335302A (ja) | 安定な医薬組成物 | |
US20080014263A1 (en) | Amorphous eprosartan mesylate and process for the preparation thereof | |
KR20220016116A (ko) | 고체 분산체 및 그것의 제조 방법 | |
WO2007102038A1 (en) | Ziprasidone formulations | |
JP6199922B2 (ja) | 化学的な安定性が向上したイルベサルタン含有錠剤 | |
CN109589312A (zh) | 一种阿立哌唑固体分散体及其制备方法 | |
TWI597063B (zh) | 藥物組成物及其製備方法 | |
CN111904960A (zh) | 一种固体分散体及药用组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18828577 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3066046 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2019568286 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019027473 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018296476 Country of ref document: AU Date of ref document: 20180703 Kind code of ref document: A Ref document number: 20207001561 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018828577 Country of ref document: EP Effective date: 20200204 |
|
ENP | Entry into the national phase |
Ref document number: 112019027473 Country of ref document: BR Kind code of ref document: A2 Effective date: 20191220 |